BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1707957)

  • 41. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis.
    Droz JP; Kramar A; Ghosn M; Piot G; Rey A; Theodore C; Wibault P; Court BH; Perrin JL; Travagli JP
    Cancer; 1988 Aug; 62(3):564-8. PubMed ID: 2455591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.
    Logothetis CJ; Swanson DA; Dexeus F; Chong C; Ogden S; Ayala AG; von Eschenbach AC; Johnson DE; Samuels ML
    J Clin Oncol; 1987 Jun; 5(6):906-11. PubMed ID: 2438389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum tumor markers and testicular germ cell tumors: a primer for radiologists.
    Marshall C; Enzerra M; Rahnemai-Azar AA; Ramaiya NH
    Abdom Radiol (NY); 2019 Mar; 44(3):1083-1090. PubMed ID: 30539249
    [TBL] [Abstract][Full Text] [Related]  

  • 44. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.
    J Clin Oncol; 1997 Feb; 15(2):594-603. PubMed ID: 9053482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
    Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
    Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89.
    Calaminus G; Schneider DT; Bökkerink JP; Gadner H; Harms D; Willers R; Göbel U
    J Clin Oncol; 2003 Mar; 21(5):781-6. PubMed ID: 12610174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy.
    Rosas Plaza X; van Agthoven T; Meijer C; van Vugt MATM; de Jong S; Gietema JA; Looijenga LHJ
    Cells; 2019 Oct; 8(10):. PubMed ID: 31597402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors.
    Lange PH
    Natl Cancer Inst Monogr; 1978 Dec; (49):215-7. PubMed ID: 86163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors.
    Swanson DA
    Semin Urol; 1993 May; 11(2):92-8. PubMed ID: 7689741
    [No Abstract]   [Full Text] [Related]  

  • 50. Prognostic factors for favorable outcome in disseminated germ cell tumors.
    Birch R; Williams S; Cone A; Einhorn L; Roark P; Turner S; Greco FA
    J Clin Oncol; 1986 Mar; 4(3):400-7. PubMed ID: 2419524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic factors in nonseminomatous testicular cancer.
    Javadpour N
    Prog Clin Biol Res; 1985; 203():271-86. PubMed ID: 2421330
    [No Abstract]   [Full Text] [Related]  

  • 52. Prognostic factors in seminomas with special respect to HCG: results of a prospective multicenter study. Seminoma Study Group.
    Weissbach L; Bussar-Maatz R; Löhrs U; Schubert GE; Mann K; Hartmann M; Dieckmann KP; Fassbinder J
    Eur Urol; 1999 Dec; 36(6):601-8. PubMed ID: 10559615
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic value of tumor marker determinations in testicular cancer patients.
    Kühböck J; Aiginger P; Kuzmits R; Spona J
    Cancer Detect Prev; 1987; 10(5-6):389-92. PubMed ID: 2436782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.
    Mazumdar M; Bajorin DF; Bacik J; Higgins G; Motzer RJ; Bosl GJ
    J Clin Oncol; 2001 May; 19(9):2534-41. PubMed ID: 11331333
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum human chorionic gonadotropin is associated with angiogenesis in germ cell testicular tumors.
    Arrieta O; Michel Ortega RM; Angeles-Sánchez J; Villarreal-Garza C; Avilés-Salas A; Chanona-Vilchis JG; Aréchaga-Ocampo E; Luévano-González A; Jiménez MA; Aguilar JL
    J Exp Clin Cancer Res; 2009 Aug; 28(1):120. PubMed ID: 19709439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
    Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
    Oncodev Biol Med; 1981; 2(1-2):117-28. PubMed ID: 6170952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of clinical stage I nonseminomatous germ cell testicular cancer.
    Choueiri TK; Stephenson AJ; Gilligan T; Klein EA
    Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature.
    Porcaro AB; Antoniolli SZ; Maffei N; Beltrami P; Bassetto MA; Curti P
    Arch Ital Urol Androl; 2002 Jun; 74(2):81-5. PubMed ID: 12161942
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.
    Toner GC; Geller NL; Lin SY; Bosl GJ
    Cancer; 1991 Apr; 67(8):2049-57. PubMed ID: 1848473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
    Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
    J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.